HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1
Author(s) -
Juan Berenguer,
José Luís Calleja,
Marisa Montes,
Ángela Gil,
Ana Moreno,
Rafael Bañares,
Teresa AldámizEchevarría,
Agustı́n Albillos,
María Jesús Téllez,
Antonio Olveira,
Lourdes Domínguez,
Inmaculada Fernández,
Javier GarcíaSamaniego,
Benjamín Polo Lorduy,
Beatriz Álvarez,
Pablo Ryan,
Jesús Barrio,
M. J. Devesa,
Laura Benítez,
Ignacio de los Santos,
Luisa García Buey,
José Sanz,
Elvira Poves,
Juan Emilio Losa,
Conrado Fernández-Rodrı́guez,
Inmaculada Jarrín,
María José Calvo,
Juan GonzálezGarcía
Publication year - 2019
Publication title -
open forum infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.546
H-Index - 35
ISSN - 2328-8957
DOI - 10.1093/ofid/ofz214
Subject(s) - medicine , ledipasvir , sofosbuvir , hepatitis c virus , coinfection , hepatitis c , odds ratio , gastroenterology , confidence interval , human immunodeficiency virus (hiv) , immunology , ribavirin , virus
The results of this large prospective study analyzing outcomes for LDV/SOF against HCV G1 in treatment-naïve noncirrhotic patients suggest that HIV infection is a predictor of treatment failure in patients with chronic hepatitis C.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom